TLDR BSX touched a 52-week low of $60.54, and is down roughly 35–36% year-to-date Stifel cut its price target from $90 to $85, citing electrophysiology hospitalTLDR BSX touched a 52-week low of $60.54, and is down roughly 35–36% year-to-date Stifel cut its price target from $90 to $85, citing electrophysiology hospital

Boston Scientific (BSX) Stock Drops 36% as Analysts Revise Targets Ahead of Earnings

2026/04/21 21:50
3분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

TLDR

  • BSX touched a 52-week low of $60.54, and is down roughly 35–36% year-to-date
  • Stifel cut its price target from $90 to $85, citing electrophysiology hospital-purchasing data ahead of Q1 2026 earnings
  • Q1 2026 earnings are due April 22, 2026
  • Multiple analysts maintain Buy/Outperform ratings despite lowered targets — RBC holds a $115 target, UBS at $105
  • InvestingPro places BSX on its Most Undervalued list with a Fair Value of $76.66

Boston Scientific’s stock has had a rough ride in 2026. BSX touched a 52-week low of $60.54 on April 21, with the stock currently trading around $60.43–$60.99 — a far cry from its 52-week high of $109.50.


BSX Stock Card
Boston Scientific Corporation, BSX

That’s a drop of about 36% year-to-date, erasing billions from the company’s $90.6 billion market cap.

Stifel analyst Rick Wise lowered his price target on BSX to $85 from $90 ahead of first-quarter 2026 earnings, which are due on April 22, 2026. He kept his Buy rating in place.

The cut was driven by monthly electrophysiology (EP) hospital-purchasing data Stifel uses to get a read on the quarter before results come in.

January data was about 92% reported, February around 85%, and March at roughly 60% — giving a partial but meaningful picture of EP revenue trends.

Stifel leaned on a comparison with Johnson & Johnson and Abbott Laboratories, using that same EP purchasing database to cross-check projected vs. actual revenues. The firm previously flagged potential downside risk to US EP consensus revenues ahead of the prior quarter using a similar method.

Analyst Targets Still Well Above Current Price

Despite the bearish price action, the analyst community hasn’t abandoned ship. Truist Securities kept its Buy rating while lowering its target to $90 from $92. The firm expects the cardiovascular segment to grow 8.5% to 9% in the upcoming report.

RBC Capital reiterated an Outperform rating with a $115 price target after speaking directly with BSX executives about growth prospects.

UBS held its Buy rating and $105 target following the CHAMPION-AF trial results for the Watchman heart implant. The trial hit all primary and secondary endpoints — a positive outcome that UBS says reduces headline risk.

There’s a wrinkle though. The Watchman device showed a slightly higher ischemic stroke rate compared to non-vitamin K antagonist oral anticoagulants (NOACs), which disappointed some investors.

Piper Sandler kept its Overweight rating after feedback from a high-volume electrophysiologist who expects Watchman usage to increase despite the stroke data.

Stock Flagged as Undervalued

InvestingPro has flagged BSX as one of its most undervalued stocks, placing its Fair Value at $76.66 — roughly 27% above where it’s currently trading.

Revenue growth has remained strong, with BSX posting nearly 20% growth over the last twelve months. That’s not a struggling business on paper — it’s a stock under pressure.

All eyes now turn to April 22, when BSX reports Q1 2026 earnings. That report will be the first real test of whether EP revenue held up as Stifel’s data suggests it might.

The post Boston Scientific (BSX) Stock Drops 36% as Analysts Revise Targets Ahead of Earnings appeared first on CoinCentral.

시장 기회
Rubic 로고
Rubic 가격(RBC)
$0.00418
$0.00418$0.00418
+20.80%
USD
Rubic (RBC) 실시간 가격 차트

SPACEX(PRE) Launchpad Is Live

SPACEX(PRE) Launchpad Is LiveSPACEX(PRE) Launchpad Is Live

Start with $100 to share 6,000 SPACEX(PRE)

면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

No Chart Skills? Still Profit

No Chart Skills? Still ProfitNo Chart Skills? Still Profit

Copy top traders in 3s with auto trading!